Jane Chung is the President of AstraZeneca Canada Inc., part of AstraZeneca PLC, one of the world’s leading biopharmaceutical companies.
Ms. Chung is a proven business and people leader with nearly twenty years of experience in the North American biopharmaceutical industry. With a strong focus on driving a culture of employee empowerment and engagement, Ms. Chung came to AZ Canada after playing a critical role in building and leading the company’s rapidly expanding Oncology franchise in the U.S. Most recently, she served as Vice President and Head of AstraZeneca’s U.S. Immuno-Oncology Franchise, where she was accountable for all aspects of marketing and sales of the company’s Immuno-Oncology medicines. Prior to this, she led the Oncology business in the U.S. West region as the Senior Commercial Business Director.
Before joining AstraZeneca, Ms. Chung held diverse roles of increasing responsibility with Onyx Pharmaceuticals, Genentech, Novartis and Pharmacia. A former practicing clinical pharmacist, her first-hand experience in patient care helps fuels her passion about the power of science to make a meaningful difference in the lives of people.
Ms Chung is currently a member of the Board of Directors with Innovative Medicines Canada (IMC), a national organization that represents and advocates for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians.
Ms. Chung holds a B.A. degree from Columbia University, New York, and earned her pharmacy degree at St. John’s University, New York.